Trial Profile
A Phase I Study of GRN163L in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Imetelstat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 24 Jan 2012 Actual end date October 2011 added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2011 Planned End Date changed from 1 Dec 2010 to 1 May 2011 as reported by ClinicalTrials.gov.